BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Receives Notice of Allowance by USPTO for Smart Medical Inhaler System

RYAH Group (CSE: RYAH) today announced that the U.S. Patent and Trademark Office (the “USPTO”) has issued a Notice of Allowance for U.S. patent application number 15/924,172, filed in respect of the company’s IoT-powered, Smart Medical Inhaler system by its wholly owned subsidiary, Potbotics Inc. The hybrid conduction and convection RYAH Smart Medical Inhaler was recently granted Medical Device Certification under ISO 13485:2016/MDSAP and EN ISO 13485:2016 standards for both its hardware and software. “Receiving this Notice of Allowance by the USPTO on our Smart Medical Inhaler is the result of dedication and great effort by all of our product team members, with particular thanks to our Product Operations Head, Jordan Medley, and our patent legal team. The application for this invention was initially filed on March 16, 2018, and was subject to several amendments along the way,” said Gregory Wagner, CEO of RYAH Group Inc. “We look forward to strengthening competitive positioning on our intellectual property and medical device portfolio with a number of patents pending maturing on our additional IoT products.”

To view the full press release, visit https://ibn.fm/570jf

About RYAH Group Inc.

RYAH is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates Health Insurance Portability and Accountability Act (“HIPAA”)-compliant patient data, intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries, pharmaceutical companies and licensed processors (“LPs”) to monitor and manage formulation effects on patients and demographics. With a strong intellectual property portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation lifecycle. For more information, visit www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork